• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 20, 2012

View Archived Issues

'Generally a Thumbs-Up' as PDUFA V Heads to Congress

BOSTON – Lawmakers reached agreement late Monday on PDUFA V. The House is expected to pass the legislation, S. 3187, Wednesday, followed by the Senate late this week or early next week, coming in well ahead of their self-imposed July 4 goal. Read More

FDA Delivers CRL for Pfizer's Rare Disease Drug Vyndaqel

Asking for a second efficacy study, the FDA issued a complete response letter (CRL) for Pfizer Inc.'s new drug application for tafamidis meglumine to treat the orphan indication of transthyretin familial amyloid polyneuropathy (TTR-FAP). Read More

Uptake of Biosimilars in Europe is Slow, Rocky

BOSTON – Mind the gap. It's not enough to chart a regulatory pathway and see biosimilar products through to approval; there remain problems with promoting uptake and delivering the promised cost savings to payers, as experience in Europe illustrates. Read More

Merck Pressing Ahead with Geneva Pullout

Despite widespread protests, including a visit from a delegation to its global headquarters in Darmstadt, Germany, and a one-day work stoppage last week, Merck KgaA is proceeding with its original plan to shutter the Geneva headquarters of its Merck Serono division and to transfer all R&D out of Switzerland. Read More

Financings Roundup

• Nuevolution A/S, of Copenhagen, Denmark, raised $13.7 million in a new financing round led by Industrifonden, with strong support by existing investors Sunstone Capital, SEB Venture Capital and SEB Utvecklingsstiftelse. Read More

Stock Movers

Read More

House Bill Ramps Up Drug Counterfeiting Penalties

WASHINGTON – Trying to increase the risks of making and peddling counterfeit drugs so they outweigh the potential financial gain, the House passed a bill Monday that puts drug counterfeiting on par with fake military products. Read More

Human Microbiome Project: 'Done a Lot,' Still Early Days

In the biotechnology world, all eyes are on Boston and the BIO 2012 convention this week. But across the country, in San Francisco, the American Society for Microbiology is also having its annual meeting. And on Tuesday, a late-breaking session at that meeting reported the newest findings of the Human Microbiome Project. Read More

Other News To Note

• Coronado Biosciences Inc., of Burlington, Mass., reported that the FDA granted orphan drug status to its biologic CNDO-109 for the treatment of acute myeloid leukemia (AML). Read More

Clinic Roundup

• NewLink Genetics Corp., of Ames, Iowa, has passed the midpoint in enrollment in its Phase III hyperacute pancreas immunotherapy product candidate (algenpantucel-L) trial with full enrollment projected to be completed by the end of 2013. Read More

Pharma: Other News To Note

• Sanofi SA, of Paris, and the Joslin Diabetes Center, of Boston, reported that they have established a collaboration that will focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogues with more targeted efficacy. Read More

Pharma: Clinic Roundup

• Pfizer Inc., of New York, said its ALK inhibitor Xalkori (crizotinib) met its primary endpoint in the PROFILE 1007 study, demonstrating significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC). Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 21, 2025.
  • HIV virus cells

    Coinfections and diversity paint the many shades of HIV cure

    BioWorld
    We all look different to HIV, a virus that destroys the immune system. The defensive cells record every interaction with foreign agents, infections from viruses...
  • Engineered IL-18 variants with improved drug-like properties show promise for cancer immunotherapy

    BioWorld Science
    Interleukin-18 (IL-18) is a pro-inflammatory cytokine that plays a crucial role in promoting antitumor immunity by activating T and natural killer (NK) cells....
  • Opportunity compass with Chinese flag

    For big pharma, China is a shopper’s dream

    BioWorld
    Big pharma is increasingly shopping in China to fill its pipelines as it faces looming patent cliffs on major blockbusters coupled with growing pricing...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe